Results 61 to 70 of about 2,290 (211)

Henoch–Schönlein purpura induced by sitagliptin: A case report

open access: yesSAGE Open Medical Case Reports
Dipeptidyl peptidase-4 inhibitors are oral antihyperglycemic medications often used as adjuncts to other antidiabetic agents to treat type 2 diabetes mellitus.
Alexa Moschella, Carly Kirshen
doaj   +1 more source

Diabetes Increases Immunotherapy‐Related Toxicity but Not Efficacy in Metastatic Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT This multicenter retrospective study evaluated the impact of type 2 diabetes mellitus (DM) on clinical outcomes and immune‐related adverse events (irAEs) in 450 patients with metastatic non‐small cell lung cancer (NSCLC) treated with second‐line nivolumab at 17 centers between 2016 and 2024. Among these patients, 118 (26.2%) had DM.
Emre Çakır   +32 more
wiley   +1 more source

Dipeptidyl peptidase-4 (DPP-4; CD26) [PDF]

open access: yesScience-Business eXchange, 2013
Cell culture studies identified DDP-4 as the receptor of human coronavirus–Erasmus Medical Center (hCoV-EMC) and suggest that blocking the protein could help treat infection.
openaire   +1 more source

Artificial intelligence driven diet‐intestinal microbiota‐host health integration: A four‐dimensional paradigm for advancing host wellness research

open access: yesiMetaOmics, EarlyView.
This graphical abstract presents a novel Diet‐Artificial Intelligence (AI)‐intestinal Microbiota–Host Health paradigm integrating microbiota‐centric pathways and an AI‐driven multi‐omics workflow. Diet shapes gut bacteria that regulate intestinal mucosal integrity, immune signaling, and gut–brain neurotransmitters to influence host health.
Tianle He   +16 more
wiley   +1 more source

Effects of Combination Treatment With Dipeptidyl Peptidase IV Inhibitor and Sulfonylurea on Glucose Levels in Rats

open access: yesJournal of Pharmacological Sciences, 2004
The effects of orally administered dipeptidyl peptidase IV (DPP-IV) inhibitor on the glucose-lowering effect of glibenclamide are still unknown. We evaluated the effects of combination treatment with a long-lasting DPP-IV inhibitor, K579 ((S)-1-[4-methyl-
Kotaro Takasaki   +4 more
doaj   +1 more source

Human biomarker navigator

open access: yesiMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li   +29 more
wiley   +1 more source

Identification of a Novel Scaffold for Inhibition of Dipeptidyl Peptidase-4

open access: yesJournal of Computational Biology, 2019
Dipeptidyl peptidase-4 (DPP-4) is considered a major drug target for type 2 diabetes mellitus (T2DM). In addition to T2DM, a regulatory role of DPP-4 was also found in cardiovascular diseases. Existing DPP-4 inhibitors have been reported to have several adverse effects.
Avinash Mishra   +5 more
openaire   +5 more sources

Binuclear Copper‐Dependent Oxidative Enzymes Involved in Fungal Natural Product Modifications

open access: yesJournal of the Chinese Chemical Society, EarlyView.
This article summarizes recent biochemical characterizations of a new enzyme family named by the authors as binuclear copper‐dependent oxidative enzymes (BiNCOs). Found in fungal natural product biosynthesis, BiNCOs catalyze diverse CH functionalization reactions, including C(sp3)H halogenation, C(sp3)H hydroxylation, C(sp3)O macrocyclization, and ...
Chen‐Yu Chiang, Masao Ohashi, Yi Tang
wiley   +1 more source

Bromelain as the enzyme of the future: A global bibliometric mapping of its applications and emerging trends

open access: yesJournal of the Science of Food and Agriculture, EarlyView.
Abstract INTRODUCTION Bromelain, a complex mixture of proteolytic enzymes primarily extracted from plants of the Bromeliaceae family, has gained prominence because of its broad industrial applicability, particularly in the food, pharmaceutical and cosmetic sectors.
Genésio José da Silva Neto   +6 more
wiley   +1 more source

PERsonalised Medicine for Intensification of Treatment (PERMIT) in type 2 diabetes mellitus: a target trial emulation from routine data

open access: yesHealth Technology Assessment
Background Evidence is required on the relative effectiveness of sulphonylureas, dipeptidyl peptidase-4 inhibitors or sodium–glucose cotransporter 2 inhibitors added to metformin for people with type 2 diabetes mellitus.
David G Lugo-Palacios   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy